New drug aims to shield heart muscle after major attack

NCT ID NCT06465303

Recruiting now Disease control Sponsor: ResoTher Pharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental drug called RTP-026 in 96 adults who have had a severe type of heart attack (STEMI). Participants receive three short infusions of the drug or a placebo. The goal is to see if RTP-026 can reduce heart muscle damage, measured by blood markers. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RTP-026 (a drug given as three 30-minute infusions)
What this could lead to: If it works, this could point toward a treatment that limits heart muscle damage after a severe heart attack, potentially improving recovery and reducing long-term heart failure risk.
What could go wrong: This is an early Phase 2 trial with only 96 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST ELEVATION MYOCARDIAL INFARCTION

Contacts and locations

Locations

Hjertecenteret, Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.